Emerging drugs for major depressive disorder
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Major depressive disorder (MDD) remains a major public health concern, and one that continues to suffer an incompletely-met need for effective and acceptable treatments. The development of antidepressants, to date, has focused primarily on increasing monoamine neurotransmission with increasing efficacy while minimizing adverse effects. Medications currently recommended as 'first-line' are far more tolerable than the older medications they replaced, but as many as 70% of patients continue to suffer significant depressive symptoms after treatment with one of these agents, and as many as 50% will discontinue a trial due to issues with acceptability. This review will summarize antidepressants that have recently entered the market as well as those still in development to help characterize the current state of antidepressant development. AREAS COVERED: Currently available first-line antidepressants are reviewed with respect to efficacy and tolerability, and their weaknesses are discussed as targets for future development. The background, clinical trial data and potential significance of the three most recently introduced antidepressants (trazodone-ER, desvenlafaxine and vilazodone) and the most recently approved augmentation agents (aripiprazole and quetiapine) are discussed. Following a review of the current market, all medications currently in Phase II or later clinical trials are listed and discussed, based on a thorough review of the US National Institutes of Health clinicaltrials.gov index for trials using medications to treat MDD and a search of the Informa Pharmaprojects database for medications currently being developed for a depression indication. Compounds thus identified were then used as search terms in a PubMed search of each medication. Based on pharmacologic properties, medications in development were grouped into those acting on: i) monoamine neurotransmission; ii) cholinergic neurotransmission; iii) glutamatergic neurotransmission; iv) opioid receptors; v) sigma receptors; vi) neurokinin receptors; vii) corticotrophin-releasing factor receptors and viii) other mechanisms. In the discussion of each, a brief review of the pharmacology and physiology of the related system is provided. Potential issues for the future of antidepressant development and an expert opinion are discussed. EXPERT OPINION: The past decade has not yielded a large number of new antidepressants and, with the possible exception of agomelatine, none of the newer medications that have been introduced have decisively addressed the several unmet needs in this area of therapeutics. Among the various novel strategies that are being evaluated, results of several small studies of ketamine suggest that drugs that modulate glutamatergic neurotransmission may hold the greatest promise for exerting rapid and large antidepressant effects in patients who have not responded to SSRIs or SNRIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“1 Efficacy of existing treatments Currently available antidepressants generally demonstrate comparable efficacy in placebo-controlled trials, with rates of complete remission of depressive symptoms ranging from about 30 to 45% in controlled trials [8].”
BackgroundNicholson, A., Kuper, H., & Hemingway, H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl338 · Cited by 1,353
Smoking, smoking cessation, and major depression
Glassman, A. H. (1990) · JAMA · doi:10.1001/jama.1990.03450120058029 · Cited by 1,207
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 2×
“, the second most widely prescribed SNRI), desvenlafaxine inhibits the serotonin transporter preferentially to the norepinephrine transporter, though at therapeutic doses it likely has effects on both neurotransmitter systems [15].”
BackgroundResultKessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1561 · Cited by 868 · cited 12×
“Beyond these medications, one mechanistically novel antidepressant, agomelatine, has been introduced outside the USA.”
BackgroundInfluentialKessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1561 · Cited by 868
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“Further, this ‘learned helplessness’ that is antagonized by conventional antidepressants is similarly reduced by the NMDA antagonists AP-7 and MK-801 [113].”
BackgroundMarcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Self-citationFurey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 1×
“Muscarinic receptors have also recently received attention as a potential focus of antidepressant pharmacology, based on the observation that scopolamine, a potent antimuscarinic, may have rapid and profound effects in unipolar depression [109,110].”
BackgroundThe economic burden of depression and the cost-effectiveness of treatment
Wang, P. S., Simon, G., & Kessler, R. C. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.139 · Cited by 403
National trends in the treatment for depression from 1998 to 2007
Marcus, S. C., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.151 · Cited by 312 · cited 1×
“8% in 2007 according to data from two nationally representative surveys of the US households [22].”
BackgroundThase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Self-citationBerman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260 · cited 1×
“Overall, the efficacy of the SGAs is generally similar, with between 5 and 10 patients receiving adjunctive therapy to obtain one additional response (NNT = 5 -- 10) [38-46].”
BackgroundSelf-citationInteractions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain
Narita, N., Hashimoto, K., Tomitaka, S.-I., & Minabe, Y. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00254-3 · Cited by 254 · cited 1×
“A number of currently used antidepressants act on these receptors in addition to their more familiar activities, and sigma-specific ligands have shown effects related to antidepressant activity in animals [139-142].”
BackgroundThe role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245 · cited 1×
“Dopamine is the major neurotransmitter in the brain’s reward system and as such is vital in the maintenance of appropriate concentration, energy, cognition and experience of pleasure, all of which are seen to be disrupted in depression [56].”
BackgroundDrevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241 · cited 1×
“Muscarinic receptors have also recently received attention as a potential focus of antidepressant pharmacology, based on the observation that scopolamine, a potent antimuscarinic, may have rapid and profound effects in unipolar depression [109,110].”
BackgroundThase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Self-citationGlutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190 · cited 1×
“Sertraline, mirtazapine, venlafaxine and escitalopram have all been found in meta-analyses to offer small benefits in efficacy over other antidepressants, though in general these advantages have been on the order of about a 5% benefit in response or remission rates [9-13].”
BackgroundPotential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180 · cited 1×
“Metabotropic glutamate receptors (mGluR) can be roughly divided into Group I receptors (mGluR1, mGluR5) which are predominantly postsynaptic, excitatory receptors, and Group II/III receptors (mGluR4, 6, 7, 8) which tend to be presynaptic and inhibitory, though there are many exceptions [126].”
BackgroundMilnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178 · cited 1×
“Levomilnacipran is the active enantiomer of milnacipran and, as such, it may be thought of as potentially the most noradrenergic of this class of dually acting antidepressants [72].”
BackgroundCorya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162 · cited 1×
“Overall, the efficacy of the SGAs is generally similar, with between 5 and 10 patients receiving adjunctive therapy to obtain one additional response (NNT = 5 -- 10) [38-46].”
BackgroundJet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs
Srinivasan, V., Singh, J., Pandi-Perumal, S. R., Brown, G. M., Spence, D. W., & Cardinali, D. P. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0065-y · Cited by 129
Rabenstein, R. L., Caldarone, B. J., & Picciotto, M. R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0568-z · Cited by 129
Reitstetter, R., Lukas, R. J., & Gruener, R. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38184-4 · Cited by 87 · cited 1×
“It seems most likely that this apparent contradiction is due to long-term nicotinic agonism (as in smokers) causing a desensitization of nicotinic receptors and thus functional antagonism [106].”
Background
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.014 · Cited by 663
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Barch, D. M., Pagliaccio, D., & Luking, K. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_376 · Cited by 218
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Metadata
- Authors
- Connolly, K. R., & Thase, M. E.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2012-02-20
- Volume
- 17
- Issue
- 1
- Pages
- 105-126
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2159835986
- Cited by
- 96
- References
- 31
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.